+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug-resistant enterococci



In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug-resistant enterococci



Diagnostic Microbiology & Infectious Disease 32(2): 95-99



This investigation used checkerboard and time-kill assays to evaluate the in vitro activity of RPR 106972 (45% pristinamycin IB and 55% pristinamycin IIB) alone and in combination with vancomycin or ampicillin +/- gentamicin against multidrug-resistant enterococci. The checkerboard procedure resulted in synergistic or additive effects in 91% of the isolates with the combination of RPR 106972 plus vancomycin versus 68% with RPR 106972 plus ampicillin. The addition of gentamicin to either combination resulted in synergistic or additive results in 100% of the isolates. Inhibitory activity was observed with the time-kill assay with mean change in log10 CFU/mL at 24 h of -0.31 for RPR 106972, 3.3 for vancomycin, -0.46 for RPR 106972 plus vancomycin, and -0.35 for RPR 106972 plus vancomycin and gentamicin. No antagonism was noted with any of the combinations. RPR 106972 demonstrates good inhibitory activity against Enterococcus faecium and may prove useful in the treatment of enterococcal infections.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010811656

Download citation: RISBibTeXText

PMID: 9823531

DOI: 10.1016/s0732-8893(98)00076-5


Related references

In vitro activity of a new oral streptogramin, RPR 106972, alone and in combination with vancomycin and gentamicin against vancomycin-resistant Enterococcus faecium. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 138, 1997

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (Quinupristin/Dalfopristin) against vancomycin-resistant enterococci. Diagnostic Microbiology and Infectious Disease 29(3): 203-205, 1997

In vitro activity of selected glycopeptides and ampicillin, alone and in combination with gentamicin, against enterococci exhibiting low-level vancomycin resistance. Pharmacotherapy 14(3): 363-364, 1994

Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrobial Agents and ChemoTherapy 36(7): 1563-1566, 1992

In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci. Journal of Antimicrobial ChemoTherapy 42(6): 836-838, 1998

In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci. Antimicrobial Agents and ChemoTherapy 4(4): 383-387, 1973

In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin-and high-level gentamicin-resistant Enterococcus faecium with the aph(2")-Id gene. Diagnostic Microbiology and Infectious Disease 37(4): 297-299, 2000

Synergistic activity of a novel cationic peptide antibiotic combined with either ampicillin or gentamicin against vancomycin-resistant enterococci. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 277, 1998

Ampicillin resistant enterococci time kill study using ampicillin vancomycin imipenem ciprofloxacin and gentamicin alone and in selected combinations. Advances in Therapy 3(2): 59-67, 1986

In vitro effect of RP59500 and ampicillin on vancomycin-resistant enterococci , singly and in combination. Abstracts of the General Meeting of the American Society for Microbiology 95: 152, 1995

Pharmacodynamics of trovafloxacin alone and in combination with ampicillin-sulbactam and doxycycline against vancomycin-resistant enterococci in an in vitro pharmacokinetic model of infection. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 12, 1996

In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagnostic Microbiology and Infectious Disease 14(4): 337-345, 1991

Bactericidal in vitro activity of daptomycin and vancomycin alone or in combination with tobramycin netilmicin or ampicillin against enterococci. Pathologie Biologie 37(4): 263-268, 1989

Daptomycin retains its in vitro activity against vancomycin-resistant and multidrug-resistant enterococci. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 174, 2001

In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, and quinupristin/dalfopristin against vancomycin-resistant Enterococcus. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 83, 1996